Loading...
XSTO
KDV B
Market cap8mUSD
Feb 09, Last price  
0.29SEK
Name

Karolinska Development AB

Chart & Performance

D1W1MN
XSTO:KDV B chart
P/E
—
P/S
42.52
EPS
—
Div Yield, %
—
Shrs. gr., 5y
26.46%
Rev. gr., 5y
-11.49%
Revenues
2m
-8.74%
2,322,00030,320,00013,895,00010,479,0009,943,0009,940,0005,030,0002,942,0005,360,0002,464,0003,073,0003,384,0002,651,0002,170,0002,300,0002,014,0001,838,000
Net income
-8m
L
-5,767,000-2,641,000-334,584,000-385,673,000-212,852,000197,163,000-375,815,000-1,054,673,000-216,832,000179,595,00030,510,000657,709,000-385,476,000353,847,000-145,038,0005,386,000-8,101,000
CFO
-28m
L+11.23%
-18,005,000-34,165,000-97,324,000-133,437,000-152,645,000-82,027,000-108,387,000-325,023,000-8,994,00011,331,00013,154,000-7,409,000-33,200,00016,701,000-32,534,000-25,021,000-27,830,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Karolinska Development AB (publ) functions as a venture capital firm, dedicating its capital to companies across various development stages, including seed, early, and growth phases. The company's investment strategy concentrates on a broad spectrum of life science and healthcare sectors, such as pharmaceutical and medical research and development, healthcare technology, gene research, advanced drug delivery solutions, biotechnology, and life science tools and services. Geographically, the firm prioritizes the Nordic region, specifically seeking opportunities within Sweden, Iceland, Norway, Finland, and Denmark. While it primarily aims to be the principal investor in its portfolio companies, it also considers collaborative investments. On an annual basis, Karolinska Development AB (publ) targets engaging in up to five new projects. The company was established in 2003 and is headquartered in Stockholm, Sweden.
URL
https://www.karolinskadevelopment.com/
IPO date
Apr 15, 2011
Employees
8
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT